# Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

> **NCT03167255** · PHASE2 · COMPLETED · sponsor: **NS Pharma, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** NS-065/NCNP-01

## Key facts

- **NCT ID:** NCT03167255
- **Lead sponsor:** NS Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-11-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167255, "Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03167255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*